Mesenchymal Stem Cell Immunomodulation in Autoimmune Epithelitis: A Focus on Sjögren's Syndrome

Disclaimer: This content is for educational purposes only, based on published research. It does not replace professional medical advice. Consult a physician.

Public and clinical interest in Sjögren’s syndrome (SS) — a chronic autoimmune epithelitis affecting salivary and lacrimal glands — has grown substantially, driven by the burden of sicca symptoms, fatigue, and limited conventional options. Recent online health platform data indicate rising searches for integrative and immunomodulatory approaches. Within this context, researchers are examining mesenchymal stem cells (MSCs) as an adjunctive, functional medicine supportive strategy that complements standard physical therapy (for orofacial and musculoskeletal rehabilitation) and nutritional interventions (anti-inflammatory diets, omega-3 support). This article positions MSC-based research within an integral medicine framework, emphasizing that such approaches are not standalone but rather part of a comprehensive care plan.

This article summarizes research only. None of the described MSC-based strategies are approved yet for clinical use. All MSC therapies are still categorized as adjunctive.

Individual results vary depending on lifestyle and underlying conditions.

Mechanisms of MSC Immunomodulation in Autoimmune Epithelitis

Current research indicates that MSCs derived from umbilical cord, adipose, or bone marrow exert immunomodulatory effects via paracrine signaling, including secretion of transforming growth factor-β (TGF-β), interleukin-10 (IL-10), and prostaglandin E2 (PGE2). In the context of Sjögren's syndrome, these factors are associated with suppression of Th1 and Th17 responses and enhancement of regulatory T cells (Tregs) (Xu et al., 2019). Preclinical models suggest that MSC administration may reduce lymphocytic infiltration into glandular tissue, thereby preserving acinar architecture.

"MSC-derived secretome has been observed to shift macrophages toward an anti-inflammatory M2 phenotype, which may help restore glandular homeostasis."

Preclinical Evidence: Observations Suggesting Reduced Lymphocytic Infiltration and Improved Glandular Function

In animal models of Sjögren's syndrome (e.g., NOD mice or antigen-induced sialadenitis), intravenous or local administration of MSCs has been associated with reduced focus scores in submandibular glands and increased stimulated salivary flow rates. A study by Alunno et al. (2019) summarized that MSC treatment was associated with decreased levels of pro-inflammatory cytokines (IFN-γ, IL-17) in salivary gland tissues. Another investigation (Song et al., 2020) reported that human umbilical cord MSCs improved tear secretion and reduced corneal damage in a murine model of dry eye disease. Despite these promising observations, robust human trials are warranted to confirm efficacy and safety. Individual results vary depending on lifestyle and underlying conditions.

Clinical Observations and the Need for Rigorous Trials

To date, limited human data exist regarding MSC infusion in patients with primary Sjögren's syndrome. A small case series (n=10) observed that allogeneic MSCs were associated with transient improvement in patient-reported xerostomia and fatigue scores, but the effects were not sustained beyond six months. No serious adverse events were reported (Alunno et al., 2019). However, these observations are preliminary, and placebo-controlled randomized trials are necessary. This adjunctive approach is not a replacement for conventional care (e.g., physical therapy, non-steroidal anti-inflammatory drugs, corticosteroid injections, bracing). Continue all treatments under the direction of your prescribing physician.

Role of Umbilical Cord-Derived MSCs in an Integral Medicine Framework

Umbilical cord (UC)-MSCs are of particular interest due to their young immunophenotype, high proliferative capacity, and low immunogenicity. Within an integral medicine framework, UC-MSCs are being explored as a supportive adjunct to conventional disease-modifying therapies (e.g., hydroxychloroquine) and lifestyle interventions. Research suggests that UC-MSCs may help modulate systemic inflammation while patients engage in physical therapy for joint/muscle pain and nutritional counseling to reduce oxidative stress. Nonetheless, no MSC product is currently approved by COFEPRIS, FDA, or EMA for the treatment of Sjögren’s syndrome. All described strategies remain categorized as adjunctive and continue to be investigated in clinical research settings.

Individual results vary depending on lifestyle and underlying conditions.

Supportive Strategies: Physical Therapy and Nutrition

Patients with Sjögren's often experience myalgia, arthralgia, and fatigue. Supervised physical therapy (low-impact strengthening, stretching) has been associated with improved functional capacity. An anti-inflammatory dietary pattern — rich in omega-3 fatty acids, antioxidants, and fiber — is supported by current nutrition science as an adjunct to medical therapy. MSC-based research does not supplant these foundational elements; rather, it is considered within a holistic, patient-centered plan.

Conclusion and Research Summary

This article summarizes published research only. None of the described MSC-based strategies are approved yet for clinical use. All MSC therapies are still categorized as adjunctive and not substitutes for standard care. Preclinical evidence indicates that MSCs may be associated with reduced lymphocytic infiltration and improved glandular function in Sjögren's syndrome models, but high-quality human trials are needed. Patients interested in regenerative medicine should consult a rheumatologist or licensed physician and remain under standard-of-care follow-up.

Medically reviewed by Dr. Guillermo Quezada, MD – May 2026, regenerative medicine specialist
Content reviewed as of March 2026